Baxter International Inc. received FDA approval for its supplemental drug application to establish its Sabinanigo, Spain, facility as an approved manufacturing site for 0.9% Sodium Chloride Injection, USP, for the U.S. market.   The approval includes product presentations in 250 mL, 500 mL and 1000 mL, which Baxter has been distributing in the U.S. to alleviate a drug shortage with the knowledge of the FDA. These three product presentations of 0.9% Sodium Chloride Injection, USP, known as saline...